



SIYU CHEN

Counsel · Shanghai

+86 21 6263 5821

siyu.chen@fangdalaw.com

PRACTICE AREA

MS. CHEN SPECIALIZES IN M&A, PRIVATE EQUITY INVESTMENT AND GENERAL CORPORATE.

Education

- Cornell Law School, LL.M.
- East China University of Political Science and Law, LL.B.

Professional Qualification

- Admitted to practice in the PRC
- Admitted to practice in the State of New York

Professional Background

- Ms. Chen joined Fangda Partners in 2016.

REPRESENTATIVE MATTERS AND CASES

- Represented TPG in its pre-IPO investment in a company engaged in medical device manufacturing and a company engaged in medical device R&D
- Represented Blackstone in its acquisition of a company engaged in manufacturing medical packaging tubes
- Represented Centurium Capital and the buyer group in their privatization of China Biologic Products (named “Asia-Pacific Deal of the Year (Equity)”, IFLR Awards, 2022)
- Represented PAG in its investment in Alphamab Oncology
- Represented Hillhouse in its equity investment in a company engaged in gene therapy R&D and manufacturing
- Represented Boyu Capital in its equity investment in Shuidichou and a company engaged in medical device manufacturing and R&D
- Represented Primavera in its equity investment in a company engaged in logistics and transportation
- Represented YF Capital in its equity investment in Livzon Mabpharm
- Represented Partners Group in its acquisition of a company engaged in display prop manufacturing and a company engaged in cross-border logistics transportation
- Represented Nexus Point in its acquisition of a company engaged in international freight forwarding business
- Represented RA Capital in its equity investment in Connect Biopharma, a company engaged in innovative drug R&D
- Represented AstraZeneca-CICC medical fund, CICC Capital, CITIC Capital, WuXi AppTec, CBC Group, Huagai Capital, Highlight Capital, CD Capital, and Shiyu Capital in their equity investments in bio-pharmaceutical enterprises, including companies engaged in medical technology, in medical services, and in new drug and medical device R&D, manufacturing and sales
- Represented Alibaba in its equity investment in Zto Express and in companies engaged in logistics transportation
- Represented Ant Financial in its acquisition of a company engaged in fresh food e-commerce
- Represented Shanghai Highly (Group) in its establishment of a joint venture with Voltas Limited in India
- Represented Enmore Group in its establishment of a joint venture with TP ICAP in China
- Represented New Horizon Health in its listing on the main board of the HKEx
- Represented FOSUN Pharma in its introduction of the COVID-19 vaccine into the PRC, Hong Kong SAR and Macao SAR
